Acadia Pharmaceuticals Surpasses $1 Billion Revenue Milestone

Acadia Pharmaceuticals surpasses $1 billion in annual revenue for the first time, driven by NUPLAZID and DAYBUE. The company forecasts 2026 revenue up to $1.28B.

Acadia Pharmaceuticals has closed its 2025 fiscal year by achieving a significant revenue milestone, with annual sales exceeding $1 billion for the first time. The company reported robust growth driven by its two flagship products, while management has already set ambitious targets for the current year. The key question for investors is whether this momentum can be sustained.

A Solid Financial Foundation and Ambitious Outlook

Financially, the company is positioned on stable ground. Acadia concluded the year with a substantial cash reserve of $820 million. This liquidity safeguards ongoing operations and provides capital to fund continued research and development initiatives.

Looking ahead, management has expressed an optimistic outlook for the new fiscal year, 2026. The company is targeting total revenue in the range of $1.22 billion to $1.28 billion. Within this projection, NUPLAZID is expected to contribute up to $790 million, while DAYBUE is forecast to generate up to $490 million.

Core Products Drive Double-Digit Growth

The financial results, released today, demonstrate a consistent upward trajectory. For the full year 2025, adjusted total revenue (Non-GAAP) increased by 14 percent to $1.083 billion. In the fourth quarter alone, revenue climbed 16 percent to reach $298 million.

This performance was anchored by the strength of the company's two primary commercial assets. NUPLAZID delivered $680 million in GAAP net product revenue for the full year. Meanwhile, DAYBUE made a significant contribution with annual sales of $391 million, including $110 million generated in the fourth quarter.

Quarterly Profit Boosted by One-Time Benefit

On the bottom line, Acadia reported a net income of $274 million, or $1.60 per diluted share, for the final quarter. Investors should note, however, that this result was significantly influenced by a discrete, one-time tax benefit of $250 million.

Clinical Pipeline Holds Key to Future Valuation

A crucial factor for the company's future valuation will be the progress of its clinical pipeline. Significant data is anticipated for the drug candidate Remlifanserin, which is being studied for the treatment of Alzheimer's disease psychosis. Results from the Phase 2 study are expected between August and October 2026 and are likely to be a major influence on market sentiment moving forward.